Tocilizumab for refractory post-COVID-19 pansclerotic morphea

J Eur Acad Dermatol Venereol. 2024 May;38(5):e364-e365. doi: 10.1111/jdv.19692. Epub 2023 Dec 11.

Authors

Neerja Saraswat¹, Durga Madhab Tripathy², Abhishek Mishra³, Abhishek Kumar⁴, Sivasami Kartik⁴, Manoj M Gopal⁵

Affiliations

¹ Dermatology, Military Hospital, Udhampur, India.
² Dermatology, Military Hospital, Agra, India.
³ Radiodiagnosis, Military Hospital, Udhampur, India.
⁴ Medicine & Rheumatology, Army Hospital (R&R), New Delhi, India.
⁵ Pathology and Histopathology, Command Hospital, Lucknow, India.

PMID: 38078570
DOI: 10.1111/jdv.19692

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
COVID-19* / complications
Female
Humans
Male
Middle Aged
SARS-CoV-2
Scleroderma, Localized* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
tocilizumab